Abstract
We present a patient with breast cancer who developed papillary serous adenocarcinoma of the ovary after 13 years of tamoxifen use. The possible association is explored and the literature is reviewed.
MeSH terms
-
Aged
-
Breast Neoplasms / drug therapy*
-
Cystadenocarcinoma, Papillary / chemically induced*
-
Estrogen Antagonists / adverse effects*
-
Female
-
Humans
-
Ovarian Neoplasms / chemically induced*
-
Tamoxifen / adverse effects*
Substances
-
Estrogen Antagonists
-
Tamoxifen